Alzheimer Europe (AE) is an NGO and has been raising awareness of all forms of dementia since 1996. It operates a common European platform through cooperation among its 36 members, which are all active…
Optogenetic Manipulation Of The Cholinergic System: Potential Implications For The Treatment Of Memory Deficits In Alzheimer’s Disease
Successful treatment of psychiatric disorders and neurodegenerative diseases depends crucially on our fundamental knowledge of how information is processed and stored by the brain. Understanding the interaction between neuromodulation and signal encoding would essentially aid the progress of…
New research out of the University of Maryland School of Public Health shows that exercise may improve
A protein secreted with insulin travels through the bloodstream and accumulates in the brains of individuals with type 2 diabetes and dementia, in the same manner as the amyloid beta (Αβ) plaques that are associated with Alzheimer’s disease, a study by researchers with the UC Davis Alzheimer’s Disease Center has found. The study is the […]
Scientists hope the pharmaceuticals could lead to the development of a silver bullet for combatting the neurodegenerative disease. Researchers at USC have found that a class of pharmaceuticals can both prevent and treat Alzheimer’s Disease in mice. The drugs, known as “TSPO ligands,” are currently used for certain types of neuroimaging.
A study in the journal, JAMA Neurology suggests that controlling or preventing risk factors such as hypertension earlier in life may limit or delay the brain changes associated with Alzheimer’s disease and other age-related neurological deterioration.
Buphenyl, an FDA-approved medication for hyperammonemia, may protect memory and prevent the progression of Alzheimer’s disease. Hyperammonemia is a life-threatening condition that can affect patients at any age. It is caused by abnormal, high levels of ammonia in the blood.
In addition to raising the risk of Alzheimer’s disease, the apolipoprotein E e4 allele appears to confer strong risks for Lewy body and Parkinson’s dementia – diseases that do not exhibit Alzheimer’s characteristic beta-amyloid plaques.
Young adult carriers of the presenilin gene mutation that invariably induces Alzheimer’s disease around the age of 45 years already show distinctive changes on functional and structural brain MRI and in amyloid-beta biomarkers when they are in their 20s and are still asymptomatic. However, amyloid-beta deposition in the grey matter of the brain does not […]
The medical illustration is provided courtesy of Alzheimer’s Disease Research, a program of BrightFocus Foundation. Among patients with Alzheimer’s disease who develop psychosis or agitation-aggression that responds to risperidone, discontinuing the drug as advised after 3-6 months is associated with a doubling of the rate of relapse, according to a […]
The imaging agent florbetapir F 18 injection (Amyvid), used to exclude a diagnosis of Alzheimer’s disease, is being evaluated for Medicare reimbursement, the Centers for Medicare and Medicaid Services has announced. The agency stated on Oct. 9 that it expected a preliminary decision by July 2013, and a final decision by October 2013.
Physicians in five countries agree: Those who diagnose and treat patients with Alzheimer’s disease need more – and better – tools to handle the job.
The vast majority of patients with Alzheimer’s disease will show agitation, delusion, and other disruptive behaviors during the course of their illnesses. These behaviors cause suffering and distress for patients and for caregivers and families, often diminishing quality of life and making care more difficult.
Measurements of five protein biomarkers in the cerebrospinal fluid helped to differentiate Alzheimer’s disease from Parkinson’s disease with dementia and from dementia with Lewy bodies in a cross-sectional study of individuals at Swedish neurology and memory disorder clinics.
Eli Lilly’s experimental Alzheimer’s drug solanezumab failed to have statistically significant benefits in the primary end points of two phase III trials but showed possible early cognitive benefits in secondary analyses, the company announced Aug. 24. The two 18-month trials, called EXPEDITION 1 and 2, randomized more than 2,050 patients with mild-to-moderate Alzheimer’s disease to […]
Long-term coffee consumption may protect against dementia in the elderly, according to an Italian study presented at the Alzheimer’s Association International Conference 2012. In the prospective population-based cohort study of adults aged 80 years or older, about three-fourths drank coffee, having started on average at the age of 19 years. Among those who were dementia-free […]
The first human trial of bexarotene, the skin cancer drug shown to clear beta-amyloid brain plaques in mice with Alzheimer’s-like pathology, will commence sometime in September. The phase Ib trial will randomize 12 healthy subjects to placebo or bexarotene (Targretin), Gary E. Landreth, Ph.D., said in an interview.
Potentially modifiable environmental factors protect against Alzheimer’s disease in older adults carrying the apolipoprotein E e4 allele, a major susceptibility gene for the late-onset form of the disease and also a risk factor for other types of dementia.
The first evidence of emerging Alzheimer’s disease surfaces at least 1 decade before the onset of the disorder, based on new neuropsychological data reported at the Alzheimer’s Association International Conference 2012. So far, though, there is no single test or battery of tests that can be performed at baseline to predict preclinical Alzheimer’s disease, acknowledged […]
Nonpharmacologic interventions bestow clinically meaningful benefits on patients with dementia, a literature review has concluded. But these aren’t one-size-fits-all activities, Dr. Clive Ballard said at the Alzheimer’s Association International Conference. Different activities improve different problems, leading to the possibility of targeted treatment.
When Alzheimer’s disease patients who took risperidone for psychoses discontinued the drug, they were more than four times more likely to relapse than were those who continued treatment in a randomized, placebo-controlled trial.
Intravenous immunoglobulin continues to slow the decline in cognitive and other functions seen in Alzheimer’s disease for at least 3 years, suggest data from an extended phase II randomized trial among 21 patients with mild to moderate disease. Compared with their counterparts who started on a placebo and crossed over to intravenous immunoglobulin (IVIG) in […]
An investigational gene-based blood test identified prodromal Alzheimer’s disease with an accuracy of 81%. The test is based on a panel of 25 genes active in biological processes associated with Alzheimer’s, Dr. Magnus Sjögren said at the Alzheimer’s Association International Conference 2012. Michele G. Sullivan/IMNG Medical Media Dr. Magnus Sjögren
The largest-ever genome sequencing project is the newest weapon in the Alzheimer’s battle. This new project will examine the genetic codes of more than 800 people, generating more than 165 terabytes – 165,000 gigabytes – of new information about Alzheimer’s disease and its genetic roots. “This is the biggest single whole-genome scan that has ever […]
Approximately one in eight Alzheimer’s disease patients who develop delirium while hospitalized will suffer at least one adverse outcome, based on data from 771 adults. The findings were published in Annals of Internal Medicine on June 18. Previous studies have shown that delirium can increase the rate of cognitive decline in AD patients, but the […]
Recurrent depression from midlife through late life increases the risk of vascular dementia, suggesting a progressive etiologic association with vascular disease, a large, long-term retrospective cohort study has shown. When depression begins only in late life, it might be part of the Alzheimer’s disease prodrome, the researchers found. Whether treatment of depression could help prevent […]
A new plan marshals the forces of funding, research, and education to fight the battle against Alzheimer’s. The National Plan to Address Alzheimer’s Disease has an ambitious, overarching goal: to prevent and effectively treat Alzheimer’s by 2025. But while focusing on the future, it does not neglect the present. The plan calls for the resources […]
The Food and Drug Administration’s approval of the first amyloid plaque-imaging agent, florbetapir F18, may usher in a “new age” in the diagnosis of Alzheimer’s disease, according to Dr. Daniel Skovronsky. “We are entering a new age in which we can evaluate patients [with cognitive decline] based on the molecular pathology in the brain,” rather […]
Monitoring for metabolic side effects proved to be infrequent for outpatients with dementia or delirium who had been prescribed antipsychotic medications at 32 Veterans Affairs medical centers. Antipsychotic medications are approved by the Food and Drug Administration for use in patients with psychotic disorders, not for those with dementia and delirium. However, they are widely […]
Patients with moderate or severe Alzheimer’s disease who continued to worsen despite treatment with donepezil appeared to retain a small but significant benefit over those who added or switched to memantine or stopped taking medication for Alzheimer’s altogether in a randomized trial. The patients in the 1-year study, DOMINO (Donepezil and Memantine in Moderate to […]
A pharmacotherapeutic approach that harnesses the amyloid-beta clearing effects of the apolipoprotein E gene while also activating microglia to clear amyloid plaques from the brains of mouse models of Alzheimer’s disease could become a new treatment strategy to test clinically. The protein product of the APOE gene – the most influential genetic risk factor for […]
Major Finding: Monthly infusion with 200 mg gantenerumab, a monoclonal antibody to amyloid-beta, resulted in an average 15% decline in the amount of brain amyloid-beta in patients with mild to moderate Alzheimer’s disease. Data Source: Randomized trial of 16 patients with mild to moderate Alzheimer’s disease given monthly infusions with 60 or 200 mg gantenerumab […]
Two new studies appear to lend strong support for the theory that an overabundance of the amyloid-beta protein is the root cause of Alzheimer’s disease. A genetic study of 1,800 residents of Iceland discovered a rare mutation that apparently protects against the disease in those who carry it, and even staves off the disease in […]
Medical foods and supplements designed to support neural health and function may soon expand treatment options for common forms of dementia based on the results of two studies. One study found that a cocktail of compounds designed to support synapse formation and function improved memory in patients with mild Alzheimer’s disease. The other found that […]
An investigational drug has shown promise in improving memory and cognition in patients with mild to moderate Alzheimer’s disease in a 6-month, randomized, placebo-controlled trial that was presented at the Alzheimer’s Association International Conference 2012. The fact that the patients were still continuing to improve on statistically significant measurements of those aspects of the disease […]
Neurologists Dr. Richard Caselli and Dr. Marwan Sabbagh discuss the direction of Alzheimer’s disease research and some of the hot topics at the 2012 Alzheimer’s Association International Conference in Vancouver, B.C. Some of the latest developments under discussion at the conference include presymptomatic clinical trials involving individuals at high risk for Alzheimer’s, the value of […]
Disordered sleep in mid- to late life is associated with an increased risk for future cognitive impairment and may alter the dynamics of the Alzheimer’s disease–associated protein amyloid-beta, according to several studies. It’s important that physicians recognize disordered sleep as a modifiable risk factor, Dr. Kristine Yaffe said in an interview.
The first-ever primary prevention trial for Alzheimer’s disease will investigate whether immunotherapy can delay – or even stop – the disease in a group of subjects who are genetically destined to develop it. The $100 million project is one of the first to receive a special federal allocation for Alzheimer’s research, as envisioned in President […]